Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1963 2
1964 2
1967 1
1974 1
1978 3
1979 3
1980 5
1981 2
1983 5
1984 6
1985 3
1986 3
1987 8
1988 7
1989 9
1990 9
1991 9
1992 11
1993 8
1994 6
1995 6
1996 5
1997 10
1998 10
1999 4
2000 8
2001 10
2002 19
2003 14
2004 10
2005 12
2006 10
2007 16
2008 21
2009 12
2010 20
2011 15
2012 16
2013 22
2014 18
2015 11
2016 15
2017 14
2018 14
2019 17
2020 16
2021 18
2022 21
2023 23
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

492 results

Results by year

Filters applied: . Clear all
Page 1
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer.
Hotta K, Hida T, Nokihara H, Morise M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Kumagai T, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Yoshimoto T, Takata S, Tamura T. Hotta K, et al. Among authors: takiguchi y. ESMO Open. 2022 Aug;7(4):100527. doi: 10.1016/j.esmoop.2022.100527. Epub 2022 Jul 14. ESMO Open. 2022. PMID: 35843080 Free PMC article. Clinical Trial.
Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer.
Kenmotsu H, Yamamoto N, Yamanaka T, Yoshiya K, Takahashi T, Ueno T, Goto K, Daga H, Ikeda N, Sugio K, Seto T, Toyooka S, Date H, Mitsudomi T, Okamoto I, Yokoi K, Saka H, Okamoto H, Takiguchi Y, Tsuboi M. Kenmotsu H, et al. Among authors: takiguchi y. J Clin Oncol. 2020 Jul 1;38(19):2187-2196. doi: 10.1200/JCO.19.02674. Epub 2020 May 14. J Clin Oncol. 2020. PMID: 32407216 Clinical Trial.
Multi-focusing surface-emitting lasers.
Hirose K, Watanabe K, Kamei H, Sugiyama T, Takiguchi Y, Kurosaka Y. Hirose K, et al. Among authors: takiguchi y. Opt Express. 2023 May 22;31(11):17137-17147. doi: 10.1364/OE.484586. Opt Express. 2023. PMID: 37381455 Free article.
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
Nakagawa K, Hida T, Nokihara H, Morise M, Azuma K, Kim YH, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Kumagai T, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Koyama R, Mitsudomi T, Yamamoto N, Asakawa T, Hayashi M, Hasegawa W, Tamura T. Nakagawa K, et al. Among authors: takiguchi y. Lung Cancer. 2020 Jan;139:195-199. doi: 10.1016/j.lungcan.2019.11.025. Epub 2019 Nov 28. Lung Cancer. 2020. PMID: 31812890
Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04).
Katakami N, Uchino J, Yokoyama T, Naito T, Kondo M, Yamada K, Kitajima H, Yoshimori K, Sato K, Saito H, Aoe K, Tsuji T, Takiguchi Y, Takayama K, Komura N, Takiguchi T, Eguchi K. Katakami N, et al. Among authors: takiguchi y. Cancer. 2018 Feb 1;124(3):606-616. doi: 10.1002/cncr.31128. Epub 2017 Dec 4. Cancer. 2018. PMID: 29205286 Free PMC article. Clinical Trial.
Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial.
Kogure Y, Iwasawa S, Saka H, Hamamoto Y, Kada A, Hashimoto H, Atagi S, Takiguchi Y, Ebi N, Inoue A, Kurata T, Okamoto I, Yamaguchi M, Harada T, Seike M, Ando M, Saito AM, Kubota K, Takenoyama M, Seto T, Yamamoto N, Gemma A. Kogure Y, et al. Among authors: takiguchi y. Lancet Healthy Longev. 2021 Dec;2(12):e791-e800. doi: 10.1016/S2666-7568(21)00255-5. Lancet Healthy Longev. 2021. PMID: 36098037 Free article. Clinical Trial.
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T. Hida T, et al. Among authors: takiguchi y. Lancet. 2017 Jul 1;390(10089):29-39. doi: 10.1016/S0140-6736(17)30565-2. Epub 2017 May 10. Lancet. 2017. PMID: 28501140 Clinical Trial.
[Osteoarthropathy].
Takiguchi Y. Takiguchi Y. Gan To Kagaku Ryoho. 2010 Jun;37(6):1011-4. Gan To Kagaku Ryoho. 2010. PMID: 20567102 Japanese.
Secondary Sclerosing Cholangitis After Emphysematous Cholecystitis.
Takahashi K, Ohyama H, Takiguchi Y, Sekine Y, Toyama S, Yamada N, Sugihara C, Kan M, Ouchi M, Nagashima H, Iino Y, Kusakabe Y, Okitsu K, Ohno I, Kato N. Takahashi K, et al. Among authors: takiguchi y. ACG Case Rep J. 2023 Mar 23;10(3):e01016. doi: 10.14309/crj.0000000000001016. eCollection 2023 Mar. ACG Case Rep J. 2023. PMID: 36968126 Free PMC article.
Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung Cancer.
Kenmotsu H, Yamamoto N, Misumi T, Yoh K, Saito H, Sugawara S, Yamazaki K, Nakagawa K, Sugio K, Seto T, Toyooka S, Date H, Mitsudomi T, Okamoto I, Yokoi K, Saka H, Okamoto H, Takiguchi Y, Takahashi T, Tsuboi M. Kenmotsu H, et al. Among authors: takiguchi y. J Clin Oncol. 2023 Dec 1;41(34):5242-5246. doi: 10.1200/JCO.23.00179. Epub 2023 Sep 1. J Clin Oncol. 2023. PMID: 37656928 Clinical Trial.
492 results